155 related articles for article (PubMed ID: 3930143)
1. Plasma levonorgestrel and progesterone levels in women treated with silastic covered rods containing levonorgestrel.
Croxatto HB; Díaz S; Brandeis A; Pavez M; Johansson ED
Contraception; 1985 Jun; 31(6):643-54. PubMed ID: 3930143
[TBL] [Abstract][Full Text] [Related]
2. Long-term reversible contraception with levonorgestrel-releasing Silastic rods.
Roy S; Mishell DR; Robertson DN; Krauss RM; Lacarra M; Duda MJ
Am J Obstet Gynecol; 1984 Apr; 148(7):1006-13. PubMed ID: 6424474
[TBL] [Abstract][Full Text] [Related]
3. Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants.
Croxatto HB; Diaz S; Pavez M; Miranda P; Brandeis A
Acta Endocrinol (Copenh); 1982 Oct; 101(2):307-11. PubMed ID: 6814139
[TBL] [Abstract][Full Text] [Related]
4. Levonorgestrel plasma levels during continuous administration with different models of subdermal implants.
Alvarez F; Brache V; Faundes A; Johansson ED; Odlind V; Nash H
Contraception; 1983 Feb; 27(2):123-30. PubMed ID: 6406138
[TBL] [Abstract][Full Text] [Related]
5. Clinical and endocrinologic study of continuous levonorgestrel administration from subcutaneous solid polydimethylsiloxane rods.
Roy S; Stanczyk F; Mishell DR; Lumkin M; Gentzschein E
Contraception; 1980 Jun; 21(6):595-615. PubMed ID: 6775868
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels of levonorgestrel and free levonorgestrel index in women using NORPLANT implants or two covered rods (NORPLANT-2).
Olsson SE; Odlind V; Johansson ED; Nordström ML
Contraception; 1987 Mar; 35(3):215-28. PubMed ID: 3111784
[TBL] [Abstract][Full Text] [Related]
7. Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills.
Alvarez F; Faundes A; Johansson E; Coutinho E
Fertil Steril; 1983 Jul; 40(1):120-3. PubMed ID: 6407876
[TBL] [Abstract][Full Text] [Related]
8. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
[TBL] [Abstract][Full Text] [Related]
9. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
[TBL] [Abstract][Full Text] [Related]
10. First year clinical experience with six levonorgestrel rods as subdermal contraception.
Faundes A; Brache de Mejias V; Leon P; Robertson D; Alvarez F
Contraception; 1979 Aug; 20(2):167-75. PubMed ID: 487818
[TBL] [Abstract][Full Text] [Related]
11. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
12. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.
Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E
Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664
[TBL] [Abstract][Full Text] [Related]
13. The interaction between sex hormone binding globulin and levonorgestrel released from vaginal rings in women.
Cekan SZ; Jia M; Landgren BM; Diczfalusy E
Contraception; 1985 Apr; 31(4):431-9. PubMed ID: 3924477
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
[TBL] [Abstract][Full Text] [Related]
15. Ultrasonic visualization of NORPLANT subdermal contraceptive devices.
Thomsen RJ; Pasquale S; Nosher J
Int J Gynaecol Obstet; 1985 Jun; 23(3):223-7. PubMed ID: 2865186
[TBL] [Abstract][Full Text] [Related]
16. Norplant contraceptive implants: rods versus capsules.
Pasquale SA; Brandeis V; Cruz RI; Kelly S; Sweeney M
Contraception; 1987 Sep; 36(3):305-16. PubMed ID: 3119287
[TBL] [Abstract][Full Text] [Related]
17. A new delivery system for contraceptive steroids.
Segal S
Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1090-2. PubMed ID: 3118719
[TBL] [Abstract][Full Text] [Related]
18. Contraception with long-acting subdermal implants. A five-year clinical trial with Silastic covered rod implants containing levonorgestrel. The International Committee for Contraception Research (ICCR) of the Population Council.
Robertson DN; Diaz S; Alvarez-Sanchez F; Holma P; Mishell DR; Coutinho E; Brache V; Croxatto HB; Faundes A; Lacarra M
Contraception; 1985 Apr; 31(4):351-9. PubMed ID: 3924476
[TBL] [Abstract][Full Text] [Related]
19. Release rates of levonorgestrel from Silastic capsules, homogeneous rods and covered rods in humans.
Robertson DN; Sivin I; Nash HA; Braun J; Dinh J
Contraception; 1983 May; 27(5):483-95. PubMed ID: 6411428
[TBL] [Abstract][Full Text] [Related]
20. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device.
Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T
Contraception; 1989 Feb; 39(2):195-204. PubMed ID: 2495893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
